DEF 14A: Arrowhead Pharmaceuticals Sets Date for 2025 Annual Stockholder Meeting, Outlines Key Proposals

Arrowhead Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on March 12, 2025, to vote on director elections, executive compensation, auditor ratification, and other matters.

Summary

• Arrowhead Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders on March 12, 2025, in a virtual format.
• Stockholders will vote on electing eight directors, approving executive compensation, determining the frequency of executive compensation votes, and ratifying KPMG LLP as independent auditors for the fiscal year ending September 30, 2025.
• The Board of Directors recommends voting for all director nominees, approving executive compensation, selecting a one-year frequency for executive compensation votes, and ratifying the appointment of KPMG LLP.
• The company's proxy materials are available online at www.proxyvote.com and www.virtualshareholdermeeting.com/ARWR2025.
• The record date for determining stockholders eligible to vote at the Annual Meeting was January 17, 2025.
• The company has engaged Okapi Partners, LLC, to encourage voting by our stockholders at an estimated cost of $15,000.
• The company had outstanding 125,073,046 shares of common stock as of January 17, 2025.

Sentiment

Score: 6

Explanation: While the company is progressing with its clinical programs and has secured significant partnerships, the increased net losses and decreased revenue raise concerns. The sentiment is neutral, reflecting both positive developments and financial challenges.

Positives

• The Board is actively engaged in corporate governance, environmental, and social responsibility oversight.
• The company maintains a cybersecurity program with direct oversight from senior management and the Board.
• Arrowhead has a vibrant and growing culture and is committed to the health and welfare of its employees.
• The company supports employee development with a competitive compensation and benefits package, internal advancement, and individualized development opportunities.
• As of September 30, 2024, women comprise 51% of the employee workforce and 45% of employee leaders at the level of director or above.
• People self-identifying as a minority comprise 27% of the employee workforce and 39% of employee leaders at the level of director or above.

Negatives

• The company recorded a net loss of $599.5 million in fiscal 2024, compared to net losses of $205.3 million in fiscal 2023 and $176.1 million in fiscal 2022.
• The company recorded a net loss per share (diluted) of ($5.00) in fiscal 2024, compared to net loss per share (diluted) of ($1.92) in fiscal 2023 and ($1.67) in fiscal 2022.
• The company generated revenue of $3.6 million in fiscal 2024, compared to revenues of $240.7 million in fiscal 2023 and $243.2 million in fiscal 2022.

Risks

• The company's success depends on the successful development and commercialization of its drug candidates, which involves significant risk and uncertainty.
• The company faces competition from other pharmaceutical and biotechnology companies.
• The company's financial performance is subject to fluctuations due to research and development expenses, clinical trial costs, and regulatory approvals.
• The company's stock price is subject to volatility and may be affected by factors beyond its control.

Future Outlook

The company is seeking regulatory approval for plozasiran for the treatment of FCS and is advancing multiple clinical programs.

Management Comments

• The Board believes that having a combined CEO and Chair is the appropriate leadership structure for us at this time as it helps promote unified leadership and direction and provide management a single, clear focus to execute our strategy and business plans.

Industry Context

Arrowhead is operating in the competitive biotechnology industry, focusing on RNAi-based therapeutics. The company's partnerships with larger pharmaceutical companies like Sarepta, Takeda, Amgen, and GSK highlight the industry trend of collaboration for drug development and commercialization.

Comparison to Industry Standards

• The average total compensation paid to the Company's non-executive directors for service in 2024 is at or below the 60th percentile of the total compensation paid to non-executive directors of its peer group.
• The compensation peer group was selected in such a manner that our market capitalization was very near the median for all peer companies.
• The compensation peer group for fiscal 2024 included companies such as ACADIA Pharmaceuticals, Insmed, Amicus Therapeutics, Intellia Therapeutics, Apellis Pharmaceuticals, Ionis Pharmaceuticals, Arcus Biosciences, Ironwood Pharmaceuticals, BioCryst Pharmaceuticals, Mirati Therapeutcis, Blueprint Medicines, Madrigal Pharmaceuticals, BridgeBio Pharma, REGENXBIO, CRISPR Therapeutics AG, Sarepta Therapeutics, Deciphera Pharmaceuticals, Ultragenyx Pharmaceuticals, Denali Therapeutics, Vir Biotechnology, and Halozyme Therapeutics.

Stakeholder Impact

• Stockholders will vote on key proposals that will impact the company's direction and governance.
• Employees are subject to the company's Corporate Code of Conduct.
• The company's sustainability efforts impact the environment and local communities.
• The company's success in developing new drugs will impact patients with unmet medical needs.

Next Steps

• Stockholders are urged to vote via the Internet or telephone as instructed, or by mail.
• The company will continue to advance its clinical programs and seek regulatory approvals.
• The company will continue to explore business development opportunities.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Executive Compensation, Director Election, KPMG, Stockholders, Arrowhead Pharmaceuticals